SCHEMBL23748161

SCHEMBL23748161

C=CCCc1ccccc1C(O)c1ccccn1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.43
KDM4E B2RXH2 3/20 0.34
RECQL P46063 1/20 0.34
TSHR P16473 2/20 0.33
SLC6A3 Q01959 2/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
BRD4 O60885 1/20 0.32
KCNA5 P22460 5/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
KCNH2 Q12809 1/20 0.32
KCNJ5 P48544 1/20 0.31
KCNJ3 P48549 1/20 0.31
SCN5A Q14524 1/20 0.31
KCND3 Q9UK17 1/20 0.31
MEN1 O00255 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748168 0.85 MAPT (0.44) MAPTKDM4ERECQLTSHRSLC6A3
SCHEMBL23748219 0.84 F2RL1 (0.43) MAPTKDM4ERECQLBRD4ALDH1A1
SCHEMBL23748227 0.83 SLC6A2 (0.33) MAPTTSHRSLC6A3SLC6A2SLC6A4
SCHEMBL23748150 0.83 MAPT (0.39) MAPTKDM4ERECQLTSHRBRD4
SCHEMBL23748201 0.80 CTSA (0.31)
SCHEMBL23748324 0.78 CYP3A4 (0.36) KDM4ESLC6A3SLC6A2SLC6A4CYP1A2
SCHEMBL23748253 0.77 MEN1 (0.39) MAPTSLC6A3SLC6A2SLC6A4ALDH1A1
SCHEMBL23748213 0.74 LIG1 (0.43) MAPTKDM4ETSHRSLC6A4ALDH1A1
SCHEMBL29864658 0.70 MAPT (0.55) MAPTKDM4ERECQLTSHRSLC6A3
SCHEMBL3048607 0.70 MAPT (0.55) MAPTKDM4ERECQLTSHRSLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS JANSSEN BIOPHARMA INC (US) 2023-01-05 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
US-11312727-B1 Macrocyclic flu endonuclease inhibitors Janssen Biopharma, Inc. (US) 2022-04-26 US disclosed
EP-3864020-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS Janssen BioPharma, Inc. (US) 2021-08-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230002409-A1 MACROCYCLIC FLU ENDONUCLEASE INHIBITORS ACE, PNP, FEN1 MAPT 2999/4885KDM4E 1592/4885RECQL 243/4885
US-11312727-B1 Macrocyclic flu endonuclease inhibitors ACE, FEN1, PNP MAPT 3026/4885KDM4E 1849/4885RECQL 134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.